You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethylphenidate
Accession NumberDB00422  (APRD00657)
TypeSmall Molecule
GroupsApproved, Investigational
Description

A central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine. [PubChem]

Structure
Thumb
Synonyms
alpha-Phenyl-2-piperidineacetic acid methyl ester
Daytrana
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidylacetate
Methylphenidan
Methylphenidate
Methylphenidatum
Metilfenidato
MPH
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aptensio XRcapsule, extended release10 mg/1oralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRcapsule, extended release60 mg/1oralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRcapsule, extended release50 mg/1oralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRcapsule, extended release40 mg/1oralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRcapsule, extended release30 mg/1oralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRcapsule, extended release20 mg/1oralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Aptensio XRcapsule, extended release15 mg/1oralRhodes Pharmaceuticals L.P.2015-04-17Not applicableUs
Biphentincapsule (extended release)60 mgoralPurdue Pharma2006-08-01Not applicableCanada
Biphentincapsule (extended release)50 mgoralPurdue Pharma2006-08-01Not applicableCanada
Biphentincapsule (extended release)40 mgoralPurdue Pharma2006-08-01Not applicableCanada
Biphentincapsule (extended release)30 mgoralPurdue Pharma2006-08-01Not applicableCanada
Biphentincapsule (extended release)10 mgoralPurdue Pharma2006-08-01Not applicableCanada
Biphentincapsule (extended release)20 mgoralPurdue Pharma2006-08-01Not applicableCanada
Biphentincapsule (extended release)15 mgoralPurdue Pharma2006-08-01Not applicableCanada
Biphentincapsule (extended release)80 mgoralPurdue Pharma2007-03-09Not applicableCanada
Concertatablet, extended release36 mg/1oralJanssen Pharmaceuticals, Inc.2000-08-01Not applicableUs
Concertatablet, extended release54 mg/1oralJanssen Pharmaceuticals, Inc.2000-08-01Not applicableUs
Concertatablet (extended-release)36 mgoralJanssen Inc2003-07-23Not applicableCanada
Concertatablet (extended-release)54 mgoralJanssen Inc2003-07-23Not applicableCanada
Concertatablet, extended release18 mg/1oralJanssen Pharmaceuticals, Inc.2000-08-01Not applicableUs
Concertatablet (extended-release)18 mgoralJanssen Inc2003-07-23Not applicableCanada
Concertatablet, extended release27 mg/1oralPhysicians Total Care, Inc.2003-11-13Not applicableUs
Concertatablet, extended release54 mg/1oralPhysicians Total Care, Inc.2003-05-08Not applicableUs
Concertatablet, extended release36 mg/1oralPhysicians Total Care, Inc.2003-03-20Not applicableUs
Concertatablet, extended release18 mg/1oralPhysicians Total Care, Inc.2003-03-21Not applicableUs
Concertatablet, extended release27 mg/1oralJanssen Pharmaceuticals, Inc.2000-08-01Not applicableUs
Concertatablet (extended-release)27 mgoralJanssen Inc2005-01-06Not applicableCanada
Daytranapatch30 mg/9htransdermalNOVEN THERAPEUTICS, LLC2006-04-06Not applicableUs
Daytranapatch20 mg/9htransdermalNOVEN THERAPEUTICS, LLC2006-04-06Not applicableUs
Daytranapatch15 mg/9htransdermalNOVEN THERAPEUTICS, LLC2006-04-06Not applicableUs
Daytranapatch10 mg/9htransdermalNOVEN THERAPEUTICS, LLC2006-04-06Not applicableUs
Metadate CDcapsule, extended release50 mg/1oralPhysicians Total Care, Inc.2011-03-02Not applicableUs
Metadate CDcapsule, extended release30 mg/1oralPhysicians Total Care, Inc.2005-08-26Not applicableUs
Metadate CDcapsule, extended release10 mg/1oralPhysicians Total Care, Inc.2005-08-26Not applicableUs
Metadate CDcapsule, extended release60 mg/1oralUnither Manufacturing, LLC2006-03-21Not applicableUs
Metadate CDcapsule, extended release50 mg/1oralUnither Manufacturing, LLC2006-03-21Not applicableUs
Metadate CDcapsule, extended release40 mg/1oralUnither Manufacturing, LLC2006-03-21Not applicableUs
Metadate CDcapsule, extended release30 mg/1oralUnither Manufacturing, LLC2003-07-22Not applicableUs
Metadate CDcapsule, extended release20 mg/1oralPhysicians Total Care, Inc.2002-12-23Not applicableUs
Metadate CDcapsule, extended release20 mg/1oralUnither Manufacturing, LLC2003-02-18Not applicableUs
Metadate CDcapsule, extended release10 mg/1oralUnither Manufacturing, LLC2003-08-12Not applicableUs
Methylintablet, chewable10 mg/1oralShionogi Inc.2010-11-01Not applicableUs
Methylintablet, chewable5 mg/1oralShionogi Inc.2010-11-01Not applicableUs
Methylintablet, chewable2.5 mg/1oralShionogi Inc.2010-11-01Not applicableUs
Methylinsolution10 mg/5mLoralShionogi Inc.2010-11-01Not applicableUs
Methylinsolution5 mg/5mLoralShionogi Inc.2010-11-01Not applicableUs
Methylphenidatecapsule, extended release40 mg/1oralSandoz Inc2015-11-24Not applicableUs
Methylphenidatetablet5 mgoralPro Doc Limitee2009-06-12Not applicableCanada
Methylphenidatecapsule, extended release30 mg/1oralSandoz Inc2015-11-24Not applicableUs
Methylphenidatecapsule, extended release20 mg/1oralSandoz Inc2015-11-24Not applicableUs
Methylphenidatetablet20 mgoralPro Doc Limitee2009-06-12Not applicableCanada
Methylphenidatetablet10 mgoralPro Doc Limitee2009-06-12Not applicableCanada
Methylphenidate HCl Oral Solutionsolution5 mg/5mLoralMallinckrodt, Inc.2013-08-01Not applicableUs
Methylphenidate HCl Oral Solutionsolution10 mg/5mLoralMallinckrodt, Inc.2013-08-01Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralSandoz Inc1955-12-31Not applicableUs
Methylphenidate Hydrochloridetablet54 mg/1oralAmerican Health Packaging2014-09-04Not applicableUs
Methylphenidate Hydrochloridetablet18 mg/1oralPhysicians Total Care, Inc.2011-06-01Not applicableUs
Methylphenidate Hydrochloridetablet18 mg/1oralAmerican Health Packaging2015-01-15Not applicableUs
Methylphenidate Hydrochloridetablet36 mg/1oralAmerican Health Packaging2014-09-04Not applicableUs
Methylphenidate Hydrochloridetablet27 mg/1oralAmerican Health Packaging2014-09-04Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralbryant ranch prepack1955-12-31Not applicableUs
Methylphenidate Hydrochloridetablet54 mg/1oralActavis Pharma, Inc.2011-04-01Not applicableUs
Methylphenidate Hydrochloridetablet18 mg/1oralAvera Mc Kennan Hospital2015-11-04Not applicableUs
Methylphenidate Hydrochloridetablet36 mg/1oralActavis Pharma, Inc.2011-04-01Not applicableUs
Methylphenidate Hydrochloridetablet27 mg/1oralActavis Pharma, Inc.2011-04-01Not applicableUs
Methylphenidate Hydrochloridetablet18 mg/1oralActavis Pharma, Inc.2011-04-01Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralSandoz Inc1955-12-31Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralSandoz Inc1955-12-31Not applicableUs
Methylphenidate Hydrochloridetablet27 mg/1oralPhysicians Total Care, Inc.2011-06-01Not applicableUs
Methylphenidate Hydrochloride CDcapsule, extended release20 mg/1oralKremers Urban Pharmaceuticals Inc.2003-02-18Not applicableUs
Methylphenidate Hydrochloride CDcapsule, extended release10 mg/1oralKremers Urban Pharmaceuticals Inc.2003-08-12Not applicableUs
Methylphenidate Hydrochloride CDcapsule, extended release60 mg/1oralKremers Urban Pharmaceuticals Inc.2006-03-21Not applicableUs
Methylphenidate Hydrochloride CDcapsule, extended release50 mg/1oralKremers Urban Pharmaceuticals Inc.2006-03-21Not applicableUs
Methylphenidate Hydrochloride CDcapsule, extended release40 mg/1oralKremers Urban Pharmaceuticals Inc.2006-03-21Not applicableUs
Methylphenidate Hydrochloride CDcapsule, extended release30 mg/1oralKremers Urban Pharmaceuticals Inc.2003-07-22Not applicableUs
Methylphenidate Hydrochloride SRtablet, film coated, extended release20 mg/1oralSandoz Inc1982-03-31Not applicableUs
Methylphenidate Tab 10mgtablet10 mgoralTechnilab Pharma Inc.1996-08-061999-01-22Canada
Methylphenidate Tab 20mgtablet20 mgoralTechnilab Pharma Inc.1996-08-061999-01-22Canada
Novo-methylphenidatetablet20.00 mgoralNovopharm LimitedNot applicableNot applicableCanada
Novo-methylphenidatetablet10.00 mgoralNovopharm LimitedNot applicableNot applicableCanada
Novo-methylphenidatetablet5.00 mgoralNovopharm LimitedNot applicableNot applicableCanada
PHL-methylphenidatetablet10 mgoralPharmel Inc2003-04-21Not applicableCanada
PHL-methylphenidatetablet20 mgoralPharmel Inc2003-04-21Not applicableCanada
PHL-methylphenidatetablet5 mgoralPharmel Inc2003-01-07Not applicableCanada
PMS-methylphenidatetablet20 mgoralPharmascience Inc1990-12-31Not applicableCanada
PMS-methylphenidatetablet10 mgoralPharmascience Inc1990-12-31Not applicableCanada
PMS-methylphenidatetablet5 mgoralPharmascience Inc1997-10-24Not applicableCanada
PMS-methylphenidate ERtablet (extended-release)54 mgoralPharmascience Inc2014-03-03Not applicableCanada
PMS-methylphenidate ERtablet (extended-release)36 mgoralPharmascience Inc2014-03-03Not applicableCanada
PMS-methylphenidate ERtablet (extended-release)27 mgoralPharmascience Inc2014-03-03Not applicableCanada
PMS-methylphenidate ERtablet (extended-release)18 mgoralPharmascience Inc2014-03-03Not applicableCanada
Quillichew ERtablet, chewable, extended release40 mg/1oralNext Wave Pharmaceuticals, Inc.2016-02-17Not applicableUs
Quillichew ERtablet, chewable, extended release30 mg/1oralNext Wave Pharmaceuticals, Inc.2016-02-17Not applicableUs
Quillichew ERtablet, chewable, extended release20 mg/1oralNext Wave Pharmaceuticals, Inc.2016-02-17Not applicableUs
Quillivant XRpowder, for suspension900 mg/180mLoralNext Wave Pharmaceuticals, Inc.2012-10-01Not applicableUs
Quillivant XRpowder, for suspension750 mg/150mLoralNext Wave Pharmaceuticals, Inc.2013-01-04Not applicableUs
Quillivant XRpowder, for suspension600 mg/120mLoralNext Wave Pharmaceuticals, Inc.2012-10-01Not applicableUs
Quillivant XRpowder, for suspension300 mg/60mLoralNext Wave Pharmaceuticals, Inc.2012-10-01Not applicableUs
Ratio-methylphenidatetablet5 mgoralTeva Canada Limited2003-05-01Not applicableCanada
Ratio-methylphenidatetablet20 mgoralTeva Canada Limited1998-01-22Not applicableCanada
Ratio-methylphenidatetablet10 mgoralTeva Canada Limited1998-01-22Not applicableCanada
Ritalintablet20 mg/1oralNovartis Pharmaceuticals Corporation1955-12-31Not applicableUs
Ritalintablet10 mg/1oralNovartis Pharmaceuticals Corporation1955-12-31Not applicableUs
Ritalintablet5 mg/1oralNovartis Pharmaceuticals Corporation1955-12-31Not applicableUs
Ritalintablet20 mg/1oralPhysicians Total Care, Inc.2000-03-10Not applicableUs
Ritalin 10mgtablet10 mgoralNovartis Pharmaceuticals Canada Inc1956-12-31Not applicableCanada
Ritalin 20mgtablet20 mgoralNovartis Pharmaceuticals Canada Inc1958-12-31Not applicableCanada
Ritalin LAcapsule, extended release20 mg/1oralNovartis Pharmaceuticals Corporation2002-06-05Not applicableUs
Ritalin LAcapsule, extended release60 mg/1oralNovartis Pharmaceuticals Corporation2015-02-01Not applicableUs
Ritalin LAcapsule, extended release10 mg/1oralNovartis Pharmaceuticals Corporation2002-06-05Not applicableUs
Ritalin LAcapsule, extended release40 mg/1oralNovartis Pharmaceuticals Corporation2002-06-05Not applicableUs
Ritalin LAcapsule, extended release30 mg/1oralNovartis Pharmaceuticals Corporation2002-06-05Not applicableUs
Ritalin-SR Tab 20mgtablet (extended-release)20 mgoralNovartis Pharmaceuticals Canada Inc1984-12-31Not applicableCanada
Sandoz Methylphenidate SRtablet (extended-release)20 mgoralSandoz Canada Incorporated2008-12-23Not applicableCanada
Teva-methylphenidate ER-Ctablet (extended-release)54 mgoralTeva Canada Limited2010-01-20Not applicableCanada
Teva-methylphenidate ER-Ctablet (extended-release)36 mgoralTeva Canada Limited2010-01-20Not applicableCanada
Teva-methylphenidate ER-Ctablet (extended-release)27 mgoralTeva Canada Limited2010-01-20Not applicableCanada
Teva-methylphenidate ER-Ctablet (extended-release)18 mgoralTeva Canada Limited2010-01-20Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-methylphenidatetablet10 mgoralApotex Inc2004-11-02Not applicableCanada
Apo-methylphenidatetablet5 mgoralApotex Inc2006-02-01Not applicableCanada
Apo-methylphenidatetablet20 mgoralApotex Inc2004-11-02Not applicableCanada
Apo-methylphenidate ERtablet (extended-release)36 mgoralApotex IncNot applicableNot applicableCanada
Apo-methylphenidate ERtablet (extended-release)27 mgoralApotex IncNot applicableNot applicableCanada
Apo-methylphenidate ERtablet (extended-release)18 mgoralApotex IncNot applicableNot applicableCanada
Apo-methylphenidate ERtablet (extended-release)54 mgoralApotex IncNot applicableNot applicableCanada
Apo-methylphenidate SRtablet (extended-release)20 mgoralApotex Inc2005-04-27Not applicableCanada
Metadate ERtablet, extended release20 mg/1oralUnither Manufacturing, LLC1988-06-01Not applicableUs
Metadate ERtablet, extended release20 mg/1oralUpstate Pharma, LLC2014-11-01Not applicableUs
Methylphenidatetablet20 mg/1oralPhysicians Total Care, Inc.2007-10-16Not applicableUs
Methylphenidatetablet5 mg/1oralSTAT Rx USA LLC1997-08-29Not applicableUs
Methylphenidatetablet5 mg/1oralPhysicians Total Care, Inc.2009-05-14Not applicableUs
Methylphenidatetablet10 mg/1oralPhysicians Total Care, Inc.2005-03-24Not applicableUs
Methylphenidate Hydrochloridetablet, extended release20 mg/1oralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate Hydrochloridesolution10 mg/5mLoralTris Pharma Inc2015-03-04Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralActavis Pharma, Inc.1997-08-29Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate Hydrochloridetablet, extended release20 mg/1oralPhysicians Total Care, Inc.1994-12-16Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralAmerican Health Packaging2014-08-19Not applicableUs
Methylphenidate Hydrochloridesolution10 mg/5mLoralBreckenridge Pharmaceutical, Inc.2010-07-01Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralbryant ranch prepack2010-02-01Not applicableUs
Methylphenidate Hydrochloridetablet, extended release18 mg/1oralAvera Mc Kennan Hospital2015-03-06Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralAmerican Health Packaging2014-08-19Not applicableUs
Methylphenidate Hydrochloridesolution5 mg/5mLoralBreckenridge Pharmaceutical, Inc.2010-07-01Not applicableUs
Methylphenidate Hydrochloridetablet, chewable2.5 mg/1oralGAVIS Pharmaceuticals, LLC2015-04-06Not applicableUs
Methylphenidate Hydrochloridetablet, extended release18 mg/1oralAv Kare, Inc.2014-10-01Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralCamber Pharmaceuticals Inc.2015-10-01Not applicableUs
Methylphenidate Hydrochloridetablet, extended release10 mg/1oralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate Hydrochloridesolution5 mg/5mLoralTris Pharma Inc2015-03-04Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralActavis Pharma, Inc.1997-08-29Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release40 mg/1oralActavis South Atlantic LLC2012-01-03Not applicableUs
Methylphenidate Hydrochloridetablet, extended release54 mg/1oralKremers Urban Pharmaceuticals Inc.2013-09-23Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralGAVIS Pharmaceuticals, LLC2016-01-20Not applicableUs
Methylphenidate Hydrochloridesolution10 mg/5mLoralGAVIS Pharmaceuticals, LLC2015-12-15Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-09-15Not applicableUs
Methylphenidate Hydrochloridesolution10 mg/5mLoralNovel Laboratories, Inc.2015-08-14Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralActavis Pharma, Inc.1997-08-29Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release30 mg/1oralActavis South Atlantic LLC2012-01-03Not applicableUs
Methylphenidate Hydrochloridetablet, extended release36 mg/1oralKremers Urban Pharmaceuticals Inc.2013-09-23Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralGAVIS Pharmaceuticals, LLC2016-01-20Not applicableUs
Methylphenidate Hydrochloridesolution5 mg/5mLoralGAVIS Pharmaceuticals, LLC2015-12-15Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release40 mg/1oralActavis Pharma, Inc.2012-01-03Not applicableUs
Methylphenidate Hydrochloridesolution5 mg/5mLoralNovel Laboratories, Inc.2015-08-14Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate Hydrochloridesolution5 mg/5mLoralCaraco Pharmaceutical Laboratories, Ltd.2012-03-01Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release20 mg/1oralActavis South Atlantic LLC2012-01-03Not applicableUs
Methylphenidate Hydrochloridetablet, extended release27 mg/1oralKremers Urban Pharmaceuticals Inc.2013-07-10Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralGAVIS Pharmaceuticals, LLC2016-01-20Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralNovel Laboratories, Inc.2015-11-13Not applicableUs
Methylphenidate Hydrochloridetablet, extended release20 mg/1oralCounty Line Pharmaceuticals, LLC2016-02-29Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release30 mg/1oralActavis Pharma, Inc.2012-01-03Not applicableUs
Methylphenidate Hydrochloridetablet, chewable10 mg/1oralNovel Laboratories, Inc.2015-02-25Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralNovel Laboratories, Inc.2015-11-13Not applicableUs
Methylphenidate Hydrochloridetablet, extended release10 mg/1oralCounty Line Pharmaceuticals, LLC2016-02-29Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release20 mg/1oralActavis Pharma, Inc.2012-01-03Not applicableUs
Methylphenidate Hydrochloridetablet, chewable5 mg/1oralNovel Laboratories, Inc.2015-02-25Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralMallinckrodt, Inc.2011-03-18Not applicableUs
Methylphenidate Hydrochloridesolution10 mg/5mLoralCaraco Pharmaceutical Laboratories, Ltd.2012-03-01Not applicableUs
Methylphenidate Hydrochloridetablet, extended release18 mg/1oralKremers Urban Pharmaceuticals Inc.2013-07-10Not applicableUs
Methylphenidate Hydrochloridetablet, extended release54 mg/1oralAv Kare, Inc.2014-10-01Not applicableUs
Methylphenidate Hydrochloridetablet, chewable2.5 mg/1oralNovel Laboratories, Inc.2015-02-25Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralQualitest Pharmaceuticals2014-09-23Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralSun Pharmaceutical Industries, Inc.2013-08-16Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralUnither Manufacturing, LLC1979-04-04Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralUpstate Pharma, LLC2014-11-01Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralNovel Laboratories, Inc.2015-11-13Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralCore Pharma, Llc2014-04-07Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release20 mg/1oralAvera Mc Kennan Hospital2015-11-04Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralQualitest Pharmaceuticals2014-09-23Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralSun Pharmaceutical Industries, Inc.2013-08-16Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralUnither Manufacturing, LLC1979-04-04Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralUpstate Pharma, LLC2014-11-01Not applicableUs
Methylphenidate Hydrochloridecapsule, extended release20 mg/1oralAmerican Health Packaging2014-12-01Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralCore Pharma, Llc2014-04-07Not applicableUs
Methylphenidate Hydrochloridetablet, chewable10 mg/1oralGAVIS Pharmaceuticals, LLC2015-04-06Not applicableUs
Methylphenidate Hydrochloridetablet, extended release36 mg/1oralAv Kare, Inc.2014-10-01Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralCamber Pharmaceuticals Inc.2015-10-01Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralQualitest Pharmaceuticals2014-09-23Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralSun Pharmaceutical Industries, Inc.2013-08-16Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralUnither Manufacturing, LLC1977-12-23Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralUpstate Pharma, LLC2014-11-01Not applicableUs
Methylphenidate Hydrochloridetablet20 mg/1oralAmerican Health Packaging2014-08-19Not applicableUs
Methylphenidate Hydrochloridetablet5 mg/1oralCore Pharma, Llc2014-04-07Not applicableUs
Methylphenidate Hydrochloridetablet, chewable5 mg/1oralGAVIS Pharmaceuticals, LLC2015-04-06Not applicableUs
Methylphenidate Hydrochloridetablet, extended release27 mg/1oralAv Kare, Inc.2014-10-01Not applicableUs
Methylphenidate Hydrochloridetablet10 mg/1oralCamber Pharmaceuticals Inc.2015-10-01Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release50 mg/1oralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release40 mg/1oralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release30 mg/1oralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release20 mg/1oralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release30 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release10 mg/1oralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release10 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Methylphenidate Hydrochloride (cd)capsule, extended release60 mg/1oralTeva Pharmaceuticals USA Inc2012-09-27Not applicableUs
Methylphenidate Hydrochloride (la)capsule, extended release40 mg/1oralTeva Pharmaceuticals USA Inc2012-07-16Not applicableUs
Methylphenidate Hydrochloride (la)capsule, extended release30 mg/1oralTeva Pharmaceuticals USA Inc2012-07-16Not applicableUs
Methylphenidate Hydrochloride (la)capsule, extended release20 mg/1oralTeva Pharmaceuticals USA Inc2012-07-16Not applicableUs
Methylphenidate Hydrochloride ERtablet, extended release10 mg/1oralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate Hydrochloride ERtablet, extended release20 mg/1oralGolden State Medical Supply, Inc.2010-05-20Not applicableUs
Methylphenidate Hydrochloride Extended Releasetablet20 mg/1oralKvk Tech, Inc.2015-06-09Not applicableUs
Methylphenidate Hydrochloride Extended Releasetablet10 mg/1oralKvk Tech, Inc.2015-06-09Not applicableUs
Methylphenidate Hydrochloride Extended-releasecapsule10 mg/1oralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releasecapsule60 mg/1oralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releasecapsule50 mg/1oralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releasetablet54 mg/1oralMallinckrodt, Inc.2012-06-30Not applicableUs
Methylphenidate Hydrochloride Extended-releasecapsule40 mg/1oralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releasetablet36 mg/1oralMallinckrodt, Inc.2012-06-30Not applicableUs
Methylphenidate Hydrochloride Extended-releasecapsule30 mg/1oralMallinckrodt, Inc.2015-09-29Not applicableUs
Methylphenidate Hydrochloride Extended-releasetablet27 mg/1oralMallinckrodt, Inc.2012-06-30Not applicableUs
Methylphenidate Hydrochloride Extended-releasecapsule20 mg/1oralMallinckrodt, Inc.2015-09-29Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Equasym XLNot Available
Medikinet XLNot Available
MetadateNot Available
QuillivantNot Available
RiphenidateNot Available
Rubifen SRNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Methylphenidate Hydrochloride
Thumb
  • InChI Key: JUMYIBMBTDDLNG-UHFFFAOYNA-N
  • Monoisotopic Mass: 269.118256596
  • Average Mass: 269.767
DBSALT000117
Categories
UNII207ZZ9QZ49
CAS number113-45-1
WeightAverage: 233.3062
Monoisotopic: 233.141578857
Chemical FormulaC14H19NO2
InChI KeyInChIKey=DUGOZIWVEXMGBE-UHFFFAOYSA-N
InChI
InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3
IUPAC Name
methyl 2-phenyl-2-(piperidin-2-yl)acetate
SMILES
COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetic acid derivatives
Direct ParentPhenylacetic acid derivatives
Alternative Parents
Substituents
  • Phenylacetate
  • Aralkylamine
  • Piperidine
  • Methyl ester
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.
PharmacodynamicsMethylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Methylphenidate also blocks the reuptake of norepinephrine and dopamine. Its mechanisms appear to be similar to those of dextroamphetamine. Furthermore, it is a racemic mixture comprised of the d- and l-threo enantiomers. The d-threo enantiomer is more pharmacologically active than the l-threo enantiomer.
Mechanism of actionMethylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Alteration of serotonergic pathways via changes in dopamine transport may result.
Related Articles
AbsorptionReadily absorbed in a biphasic manner when orally administered (tablets) to children diagnosed with ADHD and to healthy adults. In children and adults males, after administration of a single oral dose of Ritalin LA and Ritalin given in two doses 4 hours apart, peak plasma concentration is reached approximately 2 hours for the first phase and 5-6 hours for the second phase. The absolute oral bioavailability of methylphenidate in children was 22±8% for d-methylphenidate and 5±3% for l-methylphenidate. These low values suggest that methylphenidate is highly metabolized presystemically.
Volume of distribution

d-methylphenidate = 2.65 L/kg;
l-methylphenidate = 1.80 L/kg;

Protein bindingBinding to plasma proteins is low (10%-33%).
Metabolism

Methylphenidate is hepatically metabolized. More specifically, it is rapidly and extensively metabolized by carboxylesterase CES1A1. Via this enzyme, methylphenidate undergoes de-esterification to ritalinic acid (a-phenyl-2-piperidine acetic acid, PPAA), which has little to no pharmacologic activity.

Route of eliminationAfter oral administration of an immediate release formulation of methylphenidate, 78%-97% of the dose is excreted in the urine and 1%-3% in the feces in the form of metabolites within 48-96 hours. Only small quantities (<1%) of unchanged methylphenidate appear in the urine. Most of the dose is excreted in the urine as ritalinic acid (60%-86%), the remainder being accounted for by minor metabolites.
Half lifed-methylphenidate = 3-4 hours; l-methylphenidate = 1-3 hours; Ritalinic acid = 3-4 hours;
Clearance

Systemic clearance for Ritalin LA and Ritalin tablets is as follows:
d-methylphenidate= 0.40±0.12 L/h/kg;
l-methylphenidate = 0.73±0.28 L/h/kg;

ToxicitySymptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.9663
Caco-2 permeable+0.6564
P-glycoprotein substrateSubstrate0.5466
P-glycoprotein inhibitor INon-inhibitor0.7964
P-glycoprotein inhibitor IINon-inhibitor0.9601
Renal organic cation transporterInhibitor0.532
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5985
CYP450 1A2 substrateNon-inhibitor0.592
CYP450 2C9 inhibitorNon-inhibitor0.897
CYP450 2D6 inhibitorNon-inhibitor0.5245
CYP450 2C19 inhibitorNon-inhibitor0.9265
CYP450 3A4 inhibitorNon-inhibitor0.8539
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9328
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9648
BiodegradationNot ready biodegradable0.5759
Rat acute toxicity2.7718 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8466
hERG inhibition (predictor II)Non-inhibitor0.7491
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Shire development inc
  • Ucb inc
  • Novartis pharmaceuticals corp
  • Mallinckrodt inc
  • Tris pharma inc
  • Ortho mcneil janssen pharmaceutical inc
  • Able laboratories inc
  • Actavis elizabeth llc
  • Watson laboratories inc
  • Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseoral15 mg/1
Capsule (extended release)oral10 mg
Capsule (extended release)oral15 mg
Capsule (extended release)oral20 mg
Capsule (extended release)oral30 mg
Capsule (extended release)oral40 mg
Capsule (extended release)oral50 mg
Capsule (extended release)oral60 mg
Capsule (extended release)oral80 mg
Tablet (extended-release)oral18 mg
Tablet (extended-release)oral27 mg
Tablet (extended-release)oral36 mg
Tablet (extended-release)oral54 mg
Patchtransdermal10 mg/9h
Patchtransdermal15 mg/9h
Patchtransdermal20 mg/9h
Patchtransdermal30 mg/9h
Solutionoral10 mg/5mL
Solutionoral5 mg/5mL
Tabletoral18 mg/1
Tablet, chewableoral10 mg/1
Tablet, chewableoral2.5 mg/1
Tablet, chewableoral5 mg/1
Tablet, extended releaseoral10 mg/1
Tablet, extended releaseoral18 mg/1
Tablet, extended releaseoral20 mg/1
Tablet, extended releaseoral27 mg/1
Tablet, extended releaseoral36 mg/1
Tablet, extended releaseoral54 mg/1
Capsule, extended releaseoral50 mg/1
Capsuleoral10 mg/1
Capsuleoral20 mg/1
Capsuleoral30 mg/1
Capsuleoral40 mg/1
Capsuleoral50 mg/1
Capsuleoral60 mg/1
Tabletoral27 mg/1
Tabletoral36 mg/1
Tabletoral54 mg/1
Tablet, film coated, extended releaseoral20 mg/1
Tabletoral10.00 mg
Tabletoral20.00 mg
Tabletoral5.00 mg
Tabletoral10 mg
Tabletoral20 mg
Tabletoral5 mg
Tablet, chewable, extended releaseoral20 mg/1
Tablet, chewable, extended releaseoral30 mg/1
Tablet, chewable, extended releaseoral40 mg/1
Powder, for suspensionoral300 mg/60mL
Powder, for suspensionoral600 mg/120mL
Powder, for suspensionoral750 mg/150mL
Powder, for suspensionoral900 mg/180mL
Tabletoral10 mg/1
Tabletoral20 mg/1
Tabletoral5 mg/1
Capsule, extended releaseoral10 mg/1
Capsule, extended releaseoral20 mg/1
Capsule, extended releaseoral30 mg/1
Capsule, extended releaseoral40 mg/1
Capsule, extended releaseoral60 mg/1
Tablet (extended-release)oral20 mg
Prices
Unit descriptionCostUnit
Daytrana 30 15 mg/9hr Patches Box175.64USD box
Daytrana 30 30 mg/9hr Patches Box174.73USD box
Daytrana 30 10 mg/9hr Patches Box172.78USD box
Daytrana 30 20 mg/9hr Patches Box168.72USD box
Methylphenidate hcl powder44.62USD g
Concerta er 54 mg tablet25.45USD tablet
Concerta er 36 mg tablet23.38USD tablet
Concerta er 27 mg tablet22.65USD tablet
Concerta er 18 mg tablet22.11USD tablet
Metadate cd 50 mg capsule7.08USD capsule
Metadate cd 60 mg capsule7.02USD capsule
Concerta 54 mg Controlled Release Tabs6.18USD tab
Metadate cd 40 mg capsule5.77USD capsule
Concerta 36 mg Controlled Release Tabs5.72USD tab
Focalin xr 30 mg capsule5.42USD capsule
Focalin XR 20 mg 24 Hour Capsule5.31USD capsule
Daytrana 10 mg/9 hr patch5.16USD patch
Daytrana 15 mg/9 hr patch5.16USD patch
Daytrana 20 mg/9 hour patch5.16USD patch
Daytrana 30 mg/9 hour patch5.16USD patch
Focalin xr 15 mg capsule5.16USD capsule
Focalin xr 20 mg capsule5.16USD capsule
Focalin XR 30 mg 24 Hour Capsule5.15USD capsule
Focalin xr 10 mg capsule5.02USD capsule
Concerta 18 mg Controlled Release Tabs5.0USD tab
Concerta 27 mg Controlled Release Tabs5.0USD tab
Focalin XR 10 mg 24 Hour Capsule4.96USD capsule
Focalin xr 5 mg capsule4.95USD capsule
Concerta 54 mg tablet sa4.91USD tablet
Focalin XR 15 mg 24 Hour Capsule4.89USD capsule
Focalin XR 5 mg 24 Hour Capsule4.83USD capsule
Ritalin la 40 mg capsule4.55USD capsule
Concerta 36 mg tablet sa4.51USD tablet
Ritalin la 30 mg capsule4.43USD capsule
Ritalin LA 10 mg 24 Hour Capsule4.42USD capsule
Ritalin LA 20 mg 24 Hour Capsule4.42USD capsule
Ritalin LA 30 mg 24 Hour Capsule4.42USD capsule
Ritalin LA 40 mg 24 Hour Capsule4.42USD capsule
Concerta 27 mg tablet sa4.37USD tablet
Ritalin la 10 mg capsule4.33USD capsule
Ritalin la 20 mg capsule4.33USD capsule
Concerta 18 mg tablet sa4.27USD tablet
Metadate cd 20 mg capsule4.24USD capsule
Metadate cd 30 mg capsule4.24USD capsule
Metadate cd 10 mg capsule4.2USD capsule
Methylphenidate er 10 mg tablet3.24USD tablet
Ritalin SR 20 mg Controlled Release Tabs3.0USD tab
Ritalin sr 20 mg tablet2.67USD tablet
Ritalin 20 mg tablet1.87USD tablet
Focalin 10 mg tablet1.7USD tablet
Ritalin 5 mg tablet1.42USD tablet
Metadate er 20 mg tablet1.32USD tablet
Methylin ER 20 mg Controlled Release Tabs1.3USD tab
Ritalin 10 mg tablet1.29USD tablet
Metadate er 10 mg tablet sa1.28USD tablet
Focalin 5 mg tablet1.26USD tablet
Methylphenidate HCl CR 20 mg Controlled Release Tabs1.2USD tab
Methylin er 20 mg tablet1.12USD tablet
Methylphenidate HCl 20 mg tablet1.05USD tablet
Methylin ER 10 mg1.0USD tab
Methylphenidate HCl 10 mg tablet0.95USD tablet
Methylphenidate HCl 5 mg tablet0.94USD tablet
Methylin er 10 mg tablet0.84USD tablet
Focalin 2.5 mg tablet0.76USD tablet
Methylin 20 mg tablet0.69USD tablet
Methylphenidate 20 mg tablet0.69USD tablet
Ritalin 20 mg Tablet0.67USD tablet
Ritalin Sr 20 mg Extended-Release Tablet0.67USD tablet
Methylin 10 mg tablet0.48USD tablet
Methylphenidate 10 mg tablet0.48USD tablet
Ritalin 10 mg Tablet0.38USD tablet
Apo-Methylphenidate 20 mg Tablet0.37USD tablet
Apo-Methylphenidate Sr 20 mg Extended-Release Tablet0.37USD tablet
Pms-Methylphenidate 20 mg Tablet0.37USD tablet
Sandoz Methylphenidate 20 mg Extended-Release Tablet0.37USD tablet
Methylin 5 mg tablet0.33USD tablet
Methylphenidate 5 mg tablet0.33USD tablet
Apo-Methylphenidate 10 mg Tablet0.17USD tablet
Pms-Methylphenidate 10 mg Tablet0.17USD tablet
Pms-Methylphenidate 5 mg Tablet0.1USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2264852 No2005-11-012017-09-16Canada
CA2355644 No2009-01-202019-12-17Canada
US5837284 No1995-12-042015-12-04Us
US5958446 No1992-12-122012-12-12Us
US6210705 No1998-09-302018-09-30Us
US6228398 No1999-11-012019-11-01Us
US6344215 No2000-10-272020-10-27Us
US6348211 No1998-09-302018-09-30Us
US6419960 No1999-12-162019-12-16Us
US6635284 No1995-12-042015-12-04Us
US6919373 Yes1998-01-312018-01-31Us
US6930129 Yes1998-01-312018-01-31Us
US7083808 No1999-12-162019-12-16Us
US7247318 No1999-12-162019-12-16Us
US7431944 No1995-12-042015-12-04Us
US7438930 No1999-12-162019-12-16Us
US7691880 No2004-10-072024-10-07Us
US8062667 No2009-03-292029-03-29Us
US8163798 Yes1998-01-312018-01-31Us
US8202537 No2007-03-152027-03-15Us
US8287903 No2011-02-152031-02-15Us
US8465765 No2011-02-152031-02-15Us
US8563033 No2011-02-152031-02-15Us
US8580310 No1999-12-162019-12-16Us
US8629179 Yes1998-01-312018-01-31Us
US8632802 No2005-10-072025-10-07Us
US8778390 No2011-02-152031-02-15Us
US8956649 No2011-02-152031-02-15Us
US8999386 No2013-04-142033-04-14Us
US9000038 Yes1998-01-312018-01-31Us
US9029416 No1997-07-312017-07-31Us
US9034370 No2005-10-072025-10-07Us
US9040083 No2011-02-152031-02-15Us
US9066869 No1999-12-162019-12-16Us
US9144549 No1997-07-312017-07-31Us
US9295642 No2013-08-142033-08-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point224-226 °CNot Available
water solubility1255mg/LNot Available
logP0.20HANSCH,C ET AL. (1995), pH 7.2
pKa8.77SANGSTER,J (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.182 mg/mLALOGPS
logP1.47ALOGPS
logP2.25ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)9.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.33 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity66.73 m3·mol-1ChemAxon
Polarizability26.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.79 KB)
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-001i-9100000000-1a9c5badbee827946da1View in MoNA
References
Synthesis Reference

DrugSyn.org

US2512572
General References
  1. Keating GM, McClellan K, Jarvis B: Methylphenidate (OROS formulation). CNS Drugs. 2001;15(6):495-500; discussion 501-3. [PubMed:11524026 ]
  2. Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R: A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006 Dec;16(6):687-98. [PubMed:17201613 ]
  3. Fone KC, Nutt DJ: Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol. 2005 Feb;5(1):87-93. [PubMed:15661631 ]
  4. Sharma RP, Javaid JI, Pandey GN, Easton M, Davis JM: Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone. Psychiatry Res. 1990 Apr;32(1):9-17. [PubMed:2190251 ]
  5. Shults T, Kownacki AA, Woods WE, Valentine R, Dougherty J, Tobin T: Pharmacokinetics and behavioral effects of methylphenidate in Thoroughbred horses. Am J Vet Res. 1981 May;42(5):722-6. [PubMed:7258793 ]
External Links
ATC CodesN06BA04
AHFS Codes
  • 28:20.92
PDB EntriesNot Available
FDA labelDownload (178 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololMethylphenidate may decrease the antihypertensive activities of Acebutolol.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Methylphenidate.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methylphenidate.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Methylphenidate.
AliskirenMethylphenidate may decrease the antihypertensive activities of Aliskiren.
Aluminum hydroxideAluminum hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
AmantadineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Amantadine.
AmilorideMethylphenidate may decrease the antihypertensive activities of Amiloride.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methylphenidate.
AmitriptylineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Amitriptyline.
AmlodipineMethylphenidate may decrease the antihypertensive activities of Amlodipine.
AmoxapineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Amoxapine.
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Methylphenidate.
ApomorphineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Apomorphine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Methylphenidate.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Methylphenidate.
AtenololMethylphenidate may decrease the antihypertensive activities of Atenolol.
AtomoxetineAtomoxetine may increase the hypertensive activities of Methylphenidate.
Azilsartan medoxomilMethylphenidate may decrease the antihypertensive activities of Azilsartan medoxomil.
BenazeprilMethylphenidate may decrease the antihypertensive activities of Benazepril.
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Methylphenidate.
BenzquinamideThe risk or severity of adverse effects can be increased when Benzquinamide is combined with Methylphenidate.
BetaxololMethylphenidate may decrease the antihypertensive activities of Betaxolol.
BisoprololMethylphenidate may decrease the antihypertensive activities of Bisoprolol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methylphenidate.
BromocriptineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Bromocriptine.
BumetanideMethylphenidate may decrease the antihypertensive activities of Bumetanide.
Calcium carbonateCalcium carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
CandesartanMethylphenidate may decrease the antihypertensive activities of Candesartan.
CaptoprilMethylphenidate may decrease the antihypertensive activities of Captopril.
CarphenazineThe risk or severity of adverse effects can be increased when Carphenazine is combined with Methylphenidate.
CarvedilolMethylphenidate may decrease the antihypertensive activities of Carvedilol.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Methylphenidate.
ChlorothiazideMethylphenidate may decrease the antihypertensive activities of Chlorothiazide.
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Methylphenidate.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenidate.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methylphenidate.
ChlorthalidoneMethylphenidate may decrease the antihypertensive activities of Chlorthalidone.
CilazaprilMethylphenidate may decrease the antihypertensive activities of Cilazapril.
CimetidineCimetidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Methylphenidate.
ClevidipineMethylphenidate may decrease the antihypertensive activities of Clevidipine.
ClomipramineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Clomipramine.
ClonidineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Clonidine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methylphenidate.
DesfluraneMethylphenidate may increase the hypertensive activities of Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Desipramine.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Methylphenidate.
DiltiazemMethylphenidate may decrease the antihypertensive activities of Diltiazem.
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Methylphenidate.
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Methylphenidate.
DoxazosinMethylphenidate may decrease the antihypertensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Doxepin.
DoxofyllineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Doxofylline.
DronabinolDronabinol may increase the tachycardic activities of Methylphenidate.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate.
EnalaprilMethylphenidate may decrease the antihypertensive activities of Enalapril.
EnalaprilatMethylphenidate may decrease the antihypertensive activities of Enalaprilat.
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Methylphenidate.
EplerenoneMethylphenidate may decrease the antihypertensive activities of Eplerenone.
EprosartanMethylphenidate may decrease the antihypertensive activities of Eprosartan.
EsmololMethylphenidate may decrease the antihypertensive activities of Esmolol.
EsomeprazoleEsomeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Etacrynic acidMethylphenidate may decrease the antihypertensive activities of Ethacrynic acid.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Methylphenidate.
FamotidineFamotidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
FelodipineMethylphenidate may decrease the antihypertensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methylphenidate.
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Methylphenidate.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methylphenidate.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methylphenidate.
FormoterolThe risk or severity of adverse effects can be increased when Formoterol is combined with Methylphenidate.
FosinoprilMethylphenidate may decrease the antihypertensive activities of Fosinopril.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Methylphenidate.
FurosemideMethylphenidate may decrease the antihypertensive activities of Furosemide.
GuanfacineMethylphenidate may decrease the antihypertensive activities of Guanfacine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.
HydralazineMethylphenidate may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideMethylphenidate may decrease the antihypertensive activities of Hydrochlorothiazide.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methylphenidate.
ImipramineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Imipramine.
IndapamideMethylphenidate may decrease the antihypertensive activities of Indapamide.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Methylphenidate.
Ioflupane I 123Methylphenidate may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IrbesartanMethylphenidate may decrease the antihypertensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Methylphenidate.
IsofluraneMethylphenidate may increase the hypertensive activities of Isoflurane.
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Methylphenidate.
IsradipineMethylphenidate may decrease the antihypertensive activities of Isradipine.
LabetalolMethylphenidate may decrease the antihypertensive activities of Labetalol.
LansoprazoleLansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
LinezolidLinezolid may increase the hypertensive activities of Methylphenidate.
LisinoprilMethylphenidate may decrease the antihypertensive activities of Lisinopril.
LosartanMethylphenidate may decrease the antihypertensive activities of Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenidate.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenidate.
Magnesium hydroxideMagnesium hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Magnesium oxideMagnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MannitolMethylphenidate may decrease the antihypertensive activities of Mannitol.
MecamylamineMethylphenidate may decrease the antihypertensive activities of Mecamylamine.
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Methylphenidate.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methylphenidate.
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Methylphenidate.
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Methylphenidate.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methylphenidate.
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Methylphenidate.
MethyclothiazideMethylphenidate may decrease the antihypertensive activities of Methyclothiazide.
MethyldopaMethylphenidate may decrease the antihypertensive activities of Methyldopa.
MetolazoneMethylphenidate may decrease the antihypertensive activities of Metolazone.
MetoprololMethylphenidate may decrease the antihypertensive activities of Metoprolol.
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Methylphenidate.
MinoxidilMethylphenidate may decrease the antihypertensive activities of Minoxidil.
MoclobemideMoclobemide may increase the hypertensive activities of Methylphenidate.
MoexiprilMethylphenidate may decrease the antihypertensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Methylphenidate.
MoxonidineMethylphenidate may decrease the antihypertensive activities of Moxonidine.
NadololMethylphenidate may decrease the antihypertensive activities of Nadolol.
NaphazolineThe risk or severity of adverse effects can be increased when Naphazoline is combined with Methylphenidate.
NebivololMethylphenidate may decrease the antihypertensive activities of Nebivolol.
NicardipineMethylphenidate may decrease the antihypertensive activities of Nicardipine.
NifedipineMethylphenidate may decrease the antihypertensive activities of Nifedipine.
NimodipineMethylphenidate may decrease the antihypertensive activities of Nimodipine.
NisoldipineMethylphenidate may decrease the antihypertensive activities of Nisoldipine.
NitroprussideMethylphenidate may decrease the antihypertensive activities of Nitroprusside.
NizatidineNizatidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Methylphenidate.
NortriptylineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenidate.
OlmesartanMethylphenidate may decrease the antihypertensive activities of Olmesartan.
OmeprazoleOmeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methylphenidate.
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Methylphenidate.
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Methylphenidate.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate.
PantoprazolePantoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
PenbutololMethylphenidate may decrease the antihypertensive activities of Penbutolol.
PerindoprilMethylphenidate may decrease the antihypertensive activities of Perindopril.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate.
PhenelzinePhenelzine may increase the hypertensive activities of Methylphenidate.
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Methylphenidate.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Methylphenidate.
PhenoxybenzamineMethylphenidate may decrease the antihypertensive activities of Phenoxybenzamine.
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Methylphenidate.
PhentolamineMethylphenidate may decrease the antihypertensive activities of Phentolamine.
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Methylphenidate.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Methylphenidate.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Methylphenidate.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methylphenidate.
PindololMethylphenidate may decrease the antihypertensive activities of Pindolol.
PiperacetazineThe risk or severity of adverse effects can be increased when Piperacetazine is combined with Methylphenidate.
PramipexoleThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Pramipexole.
PrazosinMethylphenidate may decrease the antihypertensive activities of Prazosin.
PrimidoneThe serum concentration of the active metabolites of Primidone can be increased when Primidone is used in combination with Methylphenidate.
ProcarbazineProcarbazine may increase the hypertensive activities of Methylphenidate.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methylphenidate.
PropranololMethylphenidate may decrease the antihypertensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Protriptyline.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenidate.
QuinaprilMethylphenidate may decrease the antihypertensive activities of Quinapril.
RabeprazoleRabeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
RamiprilMethylphenidate may decrease the antihypertensive activities of Ramipril.
RanitidineRanitidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
RasagilineRasagiline may increase the hypertensive activities of Methylphenidate.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenidate.
ReserpineMethylphenidate may decrease the antihypertensive activities of Reserpine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenidate.
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Methylphenidate.
RopiniroleThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Ropinirole.
RotigotineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Rotigotine.
SalmeterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Methylphenidate.
SelegilineSelegiline may increase the hypertensive activities of Methylphenidate.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Methylphenidate.
SevofluraneMethylphenidate may increase the hypertensive activities of Sevoflurane.
Sodium bicarbonateSodium bicarbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
SotalolMethylphenidate may decrease the antihypertensive activities of Sotalol.
SpironolactoneMethylphenidate may decrease the antihypertensive activities of Spironolactone.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate.
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Methylphenidate.
TelmisartanMethylphenidate may decrease the antihypertensive activities of Telmisartan.
TerazosinMethylphenidate may decrease the antihypertensive activities of Terazosin.
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Methylphenidate.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methylphenidate.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate.
TimololMethylphenidate may decrease the antihypertensive activities of Timolol.
TorasemideMethylphenidate may decrease the antihypertensive activities of Torasemide.
TrandolaprilMethylphenidate may decrease the antihypertensive activities of Trandolapril.
TranylcypromineTranylcypromine may increase the hypertensive activities of Methylphenidate.
TriamtereneMethylphenidate may decrease the antihypertensive activities of Triamterene.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenidate.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenidate.
TrimipramineThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Trimipramine.
ValsartanMethylphenidate may decrease the antihypertensive activities of Valsartan.
VerapamilMethylphenidate may decrease the antihypertensive activities of Verapamil.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Methylphenidate.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methylphenidate.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Take on empty stomach: 1 hour before or 2 hours after meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Volkow ND, Fowler JS, Gatley SJ, Dewey SL, Wang GJ, Logan J, Ding YS, Franceschi D, Gifford A, Morgan A, Pappas N, King P: Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse. 1999 Jan;31(1):59-66. [PubMed:10025684 ]
  2. Wayment HK, Deutsch H, Schweri MM, Schenk JO: Effects of methylphenidate analogues on phenethylamine substrates for the striatal dopamine transporter: potential as amphetamine antagonists? J Neurochem. 1999 Mar;72(3):1266-74. [PubMed:10037500 ]
  3. Dresel SH, Kung MP, Huang X, Plossl K, Hou C, Shiue CY, Karp J, Kung HF: In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999 Apr;26(4):342-7. [PubMed:10199939 ]
  4. Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, Abumrad NN, Gatley SJ, Logan J, Wong C, Gifford A, Ding YS, Hitzemann R, Pappas N: Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci. 1999;65(1):PL7-12. [PubMed:10403500 ]
  5. Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D: Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93. [PubMed:10414438 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  8. Viggiano D, Vallone D, Sadile A: Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling. Neural Plast. 2004;11(1-2):97-114. [PubMed:15303308 ]
  9. Tilley MR, Gu HH: The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008 Nov;327(2):554-60. doi: 10.1124/jpet.108.141713. Epub 2008 Aug 12. [PubMed:18698001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Yang L, Wang YF, Li J, Faraone SV: Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry. 2004 Sep;43(9):1154-8. [PubMed:15322419 ]
  2. Williard RL, Middaugh LD, Zhu HJ, Patrick KS: Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol. 2007 Feb;18(1):39-51. [PubMed:17218796 ]
  3. Chuhan YS, Taukulis HK: Impairment of single-trial memory formation by oral methylphenidate in the rat. Neurobiol Learn Mem. 2006 Mar;85(2):125-31. Epub 2005 Oct 24. [PubMed:16246598 ]
  4. Gray JD, Punsoni M, Tabori NE, Melton JT, Fanslow V, Ward MJ, Zupan B, Menzer D, Rice J, Drake CT, Romeo RD, Brake WG, Torres-Reveron A, Milner TA: Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress. J Neurosci. 2007 Jul 4;27(27):7196-207. [PubMed:17611273 ]
  5. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE: Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci. 2001 Feb 15;21(4):1413-9. [PubMed:11160413 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  7. Tilley MR, Gu HH: The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008 Nov;327(2):554-60. doi: 10.1124/jpet.108.141713. Epub 2008 Aug 12. [PubMed:18698001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Dresel SH, Kung MP, Huang X, Plossl K, Hou C, Shiue CY, Karp J, Kung HF: In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999 Apr;26(4):342-7. [PubMed:10199939 ]
  2. Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D: Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93. [PubMed:10414438 ]
  3. Stehouwer JS, Jarkas N, Zeng F, Voll RJ, Williams L, Owens MJ, Votaw JR, Goodman MM: Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. J Med Chem. 2006 Nov 16;49(23):6760-7. [PubMed:17154506 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Carboxylic ester hydrolase activity
Specific Function:
Not Available
Gene Name:
CES1A1a
Uniprot ID:
Q6LAP9
Molecular Weight:
1908.25 Da
References
  1. FDA label
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on May 28, 2016 03:21